Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96E52
UPID:
OMA1_HUMAN
Alternative names:
Metalloprotease-related protein 1; Overlapping with the m-AAA protease 1 homolog
Alternative UPACC:
Q96E52; D3DQ54; Q5T3G6; Q5T3G7; Q5T3G8; Q5T3G9; Q5T3H0; Q8NBB3
Background:
Metalloendopeptidase OMA1, mitochondrial, also known as Metalloprotease-related protein 1, plays a pivotal role in mitochondrial quality control. It is activated under stress, leading to the cleavage of proteins like OPA1, UQCC3, and DELE1, crucial for mitochondrial fusion, apoptosis, and the integrated stress response. Its interaction with cardiolipin suggests a role in regulating protein turnover.
Therapeutic significance:
Understanding the role of Metalloendopeptidase OMA1, mitochondrial could open doors to potential therapeutic strategies.